Alexis Rovner
Lexi Rovner, PhD is the CEO & co-founder of 64x Bio, a spinout of Harvard Medical School and the Wyss Institute. Using novel high throughput genome engineering and screening technologies in a design loop with computational tools, 64x Bio is developing highly optimized cell lines for the manufacturing of complex biologics such as viral vectors used for gene therapies. These fundamental advances enable pharmaceutical and biotechnology companies to bring more lifesaving cell and gene therapies to patients by reducing the cost and complexity of manufacturing, a critical bottleneck in this growing market. Lexi completed her PhD at Yale University and her postdoc in George Church’s lab at Harvard Medical School, where she co-founded the company alongside George, Pam Silver, Jeff Way, and David Thompson. Lexi is a Y Combinator alum, a 2022 Endpoints 20 under 40 Next-Generation Biotech Leader, and a 2022 Bloomberg New Economy Catalyst Awardee.
64x Bio
Machine Learning and Multiplexed Libraries for Large-Scale Synthetic Biology
-
Every major AI advance was built on massive amounts of data. ChatGPT was built on top of the Internet, new coding agents train on millions of public codebases, and AlphaFold leveraged the Protein DataBank. Learn about the ways that synthetic biologists are leveraging the combination of DNA sequencing and synthesis to fuel new modeling advances.
Entrepreneurial Excellence in BioPharma: Lessons from the Frontlines
-
Join a panel of pioneering BioPharma entrepreneurs as they share their hard-earned lessons and experiences from building successful ventures in one of the most challenging and dynamic industries. This session will explore key strategies for overcoming regulatory hurdles, securing funding, navigating partnerships, and driving biopharma innovation from the lab to the marketplace.
